Clinical trial
A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease
NCT00074958 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2002
- Completion date
- July 31, 2005
- Enrollment
- 16 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.